Soud, why is it so impossible for you to see that in order to have product available for future consumption it is necessary to make and pay for it in advance, stockpile it where necessary to accomodate Chinese unknowns such as Fukangren selling one type, Aeon /Habesul another and JoJU/Lexilis as well.
Plus have sufficient left over to service the expanding US and European Markets.
You will note that the inventory has climbed 2.66 times in expenditure between quarters.
This is not a loss by any means and opens the door to expansion.
If you don't do this you cannot expand.
" Er, Sorry, we dont have any available right now, can we get back to you next month after we get the machine cranked up?"
How well would that go down with prospective clients, of which there are many?
I think you can take it as read that the management would not be doing this if this wasn't necessary.
Therefore we can look forward to the dispersal to all the corners of the globe of some serious shipments of Evolis as this is product on hand and rarin' to go.
- Forums
- ASX - By Stock
- AN1
- Ann: Appendix 4C and Notes to Appendix 4C
Ann: Appendix 4C and Notes to Appendix 4C, page-19
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online